Literature DB >> 32888946

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.

M Teresa Magone1, Iris R Hartley2, Edmond Fitzgibbon3, Rachel Bishop3, Mike Arango3, Susan Moran4, Roo Vold4, Jaydira Del Rivero5, Karen Pozo6, Jamie Streit6, Kelly L Roszko6, Michael T Collins6, Rachel I Gafni6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32888946     DOI: 10.1016/j.ophtha.2020.08.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  1 in total

1.  Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.

Authors:  Iris R Hartley; Kelly L Roszko; Xiaobai Li; Karen Pozo; Jamie Streit; Jaydira Del Rivero; M Teresa Magone; Michaele R Smith; Roo Vold; Carl L Dambkowski; Michael T Collins; Rachel I Gafni
Journal:  JBMR Plus       Date:  2022-07-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.